Share:
WILMETTE, Ill. and BELOIT, Wis., May 24, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (NASDAQ:MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional patent with the U.S. Patent and Trademark Office (USPTO) titled Bio-Targeted Radiopharmaceutical Compositions Containing Ac-225 and Methods of Preparation. Radiopharmaceutical therapy is a promising approach to treat cancer and other diseases using radioactive metals bound with proteins/antibodies to target and kill cells. Actinium-225 (Ac-225) is emerging as a radioactive isotope of choice for radiopharmaceuticals due to favorable properties such as its long half-life, high potency, and induction of localized cell death.
Monopar Therapeutics : Potential to significantly improve the yield of Actinium-based radiopharmaceuticals (Form 8-K) marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
February 11, 2021 07:30 ET | Source: Monopar Therapeutics Inc. Monopar Therapeutics Inc. Wilmette, Illinois, UNITED STATES
WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the publication of a peer-reviewed study in the
European Journal of Cancer which shows the potential utility of MNPR-101 as a uPAR imaging agent to improve surgical outcomes in bladder cancer.
Using Monopar’s proprietary humanized uPAR antibody, MNPR-101, a multimodal imaging probe was developed and tested
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada
Monopar Therapeutics Inc.February 9, 2021 GMT
WILMETTE, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life and improve the quality of life for cancer patients, today announced the issuance of a patent covering composition of matter for MNPR-101 in Canada, adding to its existing protection in key markets around the world including the US, Europe and Japan.